A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
The purpose of this study is to evaluate the diagnostic performance of \[68Ga\]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in patients with neuroendocrine neoplasms (NENs) and healthy volunteers (HVs). The data from this study will provide the evidence for diagnosis of \[68Ga\]Ga-DOTA-TATE PET/CT imaging in patient with NENs in Japan.
Neuroendocrine Neoplasms
DRUG: [68Ga]Ga-DOTA-TATE|DRUG: 68Ge/68Ga Generator
Proportion of [68Ga]Ga-DOTA-TATE positive participants (TP participants) among CIM positive participants (TP or FN participants), Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants)., Day 1|Proportion of [68Ga]Ga-DOTA-TATE negative participants (TN participants) among CIM negative participants (TN or FP participants), Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants)., Day 1
Proportion of participants who are positive on both [68Ga]Ga-DOTA-TATE PET/CT imagings and CIM (TP participants) among participants who are positive on [68Ga]Ga-DOTA TATE PET/CT imaging (TP or FP participants), Subject-level positive predictive values (PPV) is defined as the proportion of TP participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP or FP participants)., Day 1|Proportion of participants who are negative on both [68Ga]Ga-DOTA-TATE PET/CT imaging and CIM (TN participants) among participants who are negative on [68Ga]Ga-DOTA-TATE PET/CT imaging (TN or FN participants), Subject-level negative predictive values (NPV) is defined as the proportion of TN participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN or FN participants)., Day 1|Proportion of participants who have consistent results (i.e. TP or TN participants) among all participants assessed by [68Ga]Ga-DOTA-TATE PET/CT imaging and CIM, Subject-level accuracy is defined as the proportion of TP and TN participants among all patients in the EFF (i.e. TP+TN+FP+FN participants)., Day 1|Proportion of [68Ga]Ga-DOTA-TATE positive regions (TP regions) among CIM positive regions (TP or FN regions), Region-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (TP regions) among CIM positive regions (i.e. TP or FN regions)., Day 1|Proportion of [68Ga]Ga-DOTA-TATE negative regions (TN regions) among CIM negative regions (TN or FP regions), Region-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (TN regions) among CIM negative regions (i.e. TN or FP regions)., Day 1|Proportion of regions which are positive on both [68Ga]Ga-DOTA-TATE PET/CT imaging and CIM (TP regions) among regions which are positive on [68Ga]Ga-DOTA-TATE PET/CT imaging (TP or FP regions), Region-level (PPV) is defined as the proportion of regions which are positive on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM (TP regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (i.e. TP or FP regions)., Day 1|Proportion of regions who are negative on both [68Ga]Ga-DOTA-TATE PET/CT imaging and CIM (TN regions) among regions which are negative on [68Ga]Ga-DOTA-TATE PET/CT imaging (TN or FN regions), Region-level (NPV) is defined as the proportion of regions which are negative on both \[68Ga\]Ga- DOTA-TATE PET/CT imaging and CIM (TN regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (i.e. TN or FN regions)., Day 1|Proportion of regions which have consistent results (i.e. TP or TN regions) among all regions assessed by [68Ga]Ga-DOTA-TATE PET/CT imaging and CIM, Region-level accuracy is defined as the proportion of regions which are CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive (TP regions) or negative (TN regions) among regions detected by CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging (i.e. TP+TN+FP+FN regions).

Where TP, FP, TN, FN regions are defined as follows:

* TP regions are the regions which show at least one lesion based on both \[68Ga\]Ga-DOTATATE PET/CT imaging and CIM by central read.
* FP regions are the regions which show at least one lesion based on \[68Ga\]Ga-DOTATATE PET/CT imaging but do not show any lesion based on CIM by central read.
* TN regions are the regions which do not show any lesion based on both \[68Ga\]Ga-DOTATATE PET/CT imaging and CIM by central read.
* FN regions are the regions which do not show any lesion based on \[68Ga\]Ga-DOTATATE PET/CT imaging but show at least one lesion based on CIM by central read., Day 1|Number of lesions detected by [68Ga]Ga-DOTA-TATE PET/CT imaging and each CIM at region-level, For region-level, number of lesion detected by \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM will be counted.

Regarding \[68Ga\]Ga-DOTA-TATE PET/CT imaging, individual and mean number of lesions detected by each 3 central readers will be presented. Regarding CIM, each number of lesions detected by \[111In\]In-Pentetreotide SPECT/CT and High Resolution CT with contrast (or MRI if CT with contrast is medically contraindicated) will be presented., Day 1|Percentage of patients who underwent a change in intended treatment plan attributed to the [68Ga]Ga-DOTA-TATE PET/CT imaging as assessed by pre and post imaging questionnaires, Numbers and percentages of participants for each intended treatment plan collected from physician at pre and post \[68Ga\]Ga-DOTA-TATE PET/CT imaging will be summarized.

Summary statistics of participants for the change of intended treatment plan will also be presented., Day 1|Inter-reader agreement on [68Ga]Ga-DOTA-TATE PET/CT imaging, Inter-reader variability for \[68Ga\]Ga-DOTA-TATE PET/CT imaging is defined as agreement rate among reader determinations and will be assessed by Fleiss' Kappa statistics. Inter-reader variability (%) and its normality 95% CI will be presented., Day 1|Lesion-level concordance rate for SSTR between [68Ga]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among lesions that local histopathology result are available, The lesion-level concordance rate for SSTR between \[68Ga\]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among legions which is available, will be calculated. The rate is defined as the proportion of lesions which are positive or negative on both local read of \[68Ga\]Ga-DOTA-TATE PET/CT imaging and local histopathology among lesions detected by local histopathology., Day 1 to Day 30|Incidence of Treatment emergent adverse event (TEAE) within 8 days after [68Ga]Ga-DOTATATE administration, The incidence of treatment-emergent adverse events (new or worsening from baseline) will be summarized by system organ class and or preferred term, severity (based on CTCAE grades), type of adverse event, relation to study treatment., Day1 to Day 8|Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of [68Ga]Ga-DOTA-TATE, Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-inf) will be listed and summarized using descriptive statistics., Day 1 (Pre-dose, 5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)|Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of [68Ga]Ga-DOTA-TATE, Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUClast will be listed and summarized using descriptive statistics., Day 1 (Pre-dose, 5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)|Observed maximum plasma concentration (Cmax) of [68Ga]Ga-DOTA-TATE, Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics., Day 1 (Pre-dose, 5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)|Time of maximum observed drug concentration occurrence (Tmax) of [68Ga]Ga-DOTA-TATE, Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Tmax will be listed and summarized using descriptive statistics., Day 1 (Pre-dose, 5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)|Terminal elimination half-life (T1/2) of [68Ga]Ga-DOTA-TATE, Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. The half-live will be listed and summarized using descriptive statistics., Day 1 (Pre-dose, 5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)|Total systemic clearance for intravenous administration (CL) of [68Ga]Ga-DOTA-TATE, Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. CL will be listed and summarized using descriptive statistics., Day 1 (Pre-dose, 5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)|Volume of distribution during the terminal phase following intravenous elimination (Vz) of [68Ga]Ga-DOTA-TATE, Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Vz will be listed and summarized using descriptive statistics., Day 1 (Pre-dose, 5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
All enrolled participants will undergo \[68Ga\]Ga-DOTA-TATE PET/CT imaging. \[68Ga\]Ga-DOTA-TATE will be administered intravenously at a dose of 2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi), and PET/CT imaging will be acquired 40 to 90 minutes after the intravenous administration of \[68Ga\]Ga-DOTA-TATE.

* Duration of screening period is up to 35 days
* Imaging period will be completed within one day followed by safety follow up visit (Day 8) after imaging day (Day 1)